R&D at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s R&D?
- Praxis Precision Medicines, Inc. (PRAX) reported R&D of $77.99M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s R&D changed year-over-year?
- Praxis Precision Medicines, Inc.'s R&D increased by 28.3% year-over-year, from $60.81M to $77.99M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s R&D?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s R&D has grown at a 22.1% compound annual growth rate (CAGR), from $120.26M to $267.12M.
- What does R&D mean?
- The costs associated with creating new products or improving existing ones.
- How do you interpret R&D?
- Higher spending indicates a commitment to future innovation, though it directly reduces current profitability.
- How does R&D compare across companies?
- Highly variable based on the stage of the clinical pipeline compared to other biotech firms.